Gut Liver.  2011 Jun;5(2):217-220.

The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea

• Cho HC
• Kim YJ
• Choi MS
• Lee JH
• Koh KC
• Yoo BC
• Paik SW

Abstract

BACKGROUND/AIMS
The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD).
METHODS
Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48.
RESULTS
The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not significantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72.
CONCLUSIONS
HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.

Keyword

Chronic hepatitis B; Hepatitis B virus related liver cirrhosis; Hepatitis A virus vaccination

MeSH Terms

Antibodies
Female
Hepatitis
Hepatitis A
Hepatitis A Antibodies
Hepatitis A virus
Hepatitis B
Hepatitis B virus
Hepatitis B, Chronic
Humans
Immunoglobulin G
Korea
Liver
Liver Diseases
Male
Vaccination
Antibodies
Hepatitis A Antibodies
Immunoglobulin G